Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
In the parent study, 24 weeks of low-dose semaglutide (1 mg subcutaneously weekly) significantly reduced IHTG by 31.3%, improved insulin sensitivity (approximately 1.5-unit decrease in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)), and lowered triglyceride levels by 27 mg/dL 12
Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
One STEP-HFpEF trial analysis showed that patients with obesity-related HFpEF on semaglutide achieved cardiac remodeling benefits beyond the impact of weight loss
A., & Jones, D
Administered through injections, usually a swift and discomfort-free method
US$ 26.51
US$ 20.03
US$ 26.52
US$ 27.93
US$ 20.94
US$ 22.11
US$ 20.71
US$ 25.16
US$ 20.81
